10-K: Impact BioMedical Inc. Files 2023 Annual Report, Highlights Progress in Drug Development and Licensing

Impact BioMedical Inc. released its 2023 annual report, detailing its financial status, ongoing research, and strategic partnerships in the biotechnology sector.

Summary

• Impact BioMedical Inc. (IBIO) is a subsidiary of DSS, Inc. focused on discovering, confirming, and patenting unique science and technologies for human healthcare and wellness.
• The company collaborates with external partners through licensing, co-development, and joint ventures.
• IBIO's operations are primarily conducted through its subsidiaries: Global BioLife, Inc., Impact BioLife Science, Inc., Global BioMedical, Inc., and Sweet Sense, Inc.
• Key technologies include Linebacker, a platform of small molecule compounds for oncology and inflammatory disorders; Laetose, a sugar alternative; Functional Fragrance Formulation (3F) for antimicrobial and insect repellent applications; and Equivir, an antiviral blend of polyphenols.
• In 2023, IBIO issued approximately 8.821 million shares as part of a stock dividend distribution and filed a registration statement for a proposed initial public offering.
• The company also disclosed a reverse stock split of 1 for 55 and a conversion of certain common stock into preferred stock.
• For the year ended December 31, 2023, IBIO reported a net loss of $4.407 million, compared to a net loss of $7.255 million in 2022.
• The company's revenue decreased from $50,000 in 2022 to $0 in 2023, due to the absence of milestone payments from licensing agreements.
• Operating expenses totaled $4.028 million in 2023, up from $3.454 million in 2022, primarily due to increased professional services and other operating costs.
• IBIO has a revolving promissory note with DSS, its majority shareholder, which has been extended to September 30, 2030, and DSS intends to continue funding the company's operations.
• The company is actively seeking to monetize its intellectual properties and control operating costs, while also pursuing an initial public offering.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in technology and partnerships, the lack of revenue, increasing expenses, and internal control weaknesses raise concerns. The company's future is heavily reliant on successful clinical trials, licensing agreements, and a successful IPO.

Positives

• The company has a diverse portfolio of promising technologies in development.
• Licensing agreements with ProPhase Labs for Linebacker and Equivir provide potential future revenue streams.
• The company is actively seeking partners for further development and commercialization of Laetose and 3F.
• The net loss decreased by 39% year-over-year, indicating improved financial performance.
• The company has secured continued funding from its majority shareholder, DSS, through a revolving promissory note.
• The company is actively pursuing an initial public offering to raise additional capital.

Negatives

• The company reported no revenue for the year ended December 31, 2023.
• Operating expenses increased by 17% year-over-year.
• The company has incurred significant operating losses since its inception and expects to continue to incur losses.
• The company has a limited operating history and no significant revenue.
• The company's ability to continue as a going concern is dependent on continued funding from DSS and successful monetization of intellectual property.
• The company's internal controls over financial reporting were deemed not effective as of December 31, 2023.

Risks

• The company's success depends on the ability to protect its intellectual property rights.
• New legislation or regulations related to patents could increase operating costs and decrease potential revenue.
• Safety and effectiveness concerns can negatively impact sales and lead to litigation.
• The company faces significant competition from other biopharmaceutical and consumer product companies.
• The company is dependent on collaborative agreements for product development and business development.
• The company may not have adequate funds to implement its business plan.
• The company's ability to resell and/or license its products will depend upon successful clinical trials.
• The company is increasingly dependent on information technology systems, making it vulnerable to cyber-attacks.
• The company relies on third parties for manufacturing of clinical drug supplies.
• The market price of the company's common stock may be highly volatile.
• The company does not anticipate paying any dividends in the foreseeable future.

Future Outlook

The company anticipates generating significant revenue growth through securing new milestone and royalty licensing revenue with Laetose and Functional Fragrance Formulation (3F) going forward. The company also expects preliminary results from ProPhase's clinical studies of Linebacker and Equivir in the first quarter of 2024, with a potential over-the-counter launch in the second half of 2024.

Management Comments

• The company is focused on scientifically tested, high-impact solutions to global problems.
• The company is committed to both funding research and developing its intellectual property portfolio.
• Management intends to take actions necessary to continue as a going concern, including monetization of intellectual properties and tightly controlling operating costs.
• The company has increased its efforts to raise additional capital through an initial public offering.

Industry Context

Impact BioMedical operates in the competitive biotechnology and pharmaceutical industry, facing competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic and governmental research institutions. The company's focus on innovative drug discovery and natural compounds aligns with current trends in the healthcare and wellness sectors.

Comparison to Industry Standards

• The company's lack of revenue is not uncommon for early-stage biotech companies focused on research and development.
• The company's reliance on licensing agreements for revenue generation is a common strategy in the biotech industry.
• The company's focus on natural compounds and alternative therapies aligns with current market trends.
• The company's operating expenses are typical for a company in its stage of development, but the increase year-over-year is a concern.
• The company's pursuit of an IPO is a common strategy for biotech companies seeking to raise capital for further development and commercialization.
• The company's internal control weaknesses are a concern and need to be addressed to meet industry standards for public companies.

Corporate Governance

Related Party Transactions

• The company has a revolving promissory note with DSS, its majority shareholder.
• The company funds the scientific operations of GRDG, a related party.
• The company incurs general and administrative costs from DSS, a related party.
• The company sold healthcare products to SHRG, a related party, which were subsequently written off as uncollectible.
• The company entered into a Stock Purchase Agreement with Vivacitas Oncology Inc., a related party.
• The company entered into an agreement with Alset EHome International, Inc., a related party, to purchase Impact Oncology PTE Ltd.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and the potential for future growth.
• Employees are impacted by the company's financial stability and future prospects.
• Customers and partners are impacted by the company's ability to develop and commercialize its technologies.
• Creditors are impacted by the company's ability to repay its debts.
• The company's success will have a positive impact on the healthcare and wellness sectors.

Next Steps

• The company will continue to develop and test its proprietary technologies.
• The company will seek to secure new milestone and royalty licensing revenue with Laetose and Functional Fragrance Formulation (3F).
• The company will continue to pursue an initial public offering.
• The company will address the identified weaknesses in its internal control over financial reporting.
• The company will monitor the progress of ProPhase's clinical studies of Linebacker and Equivir.

Key Dates

Keywords

biotechnology, pharmaceuticals, drug discovery, licensing, intellectual property, oncology, neurology, immunology, antivirals, sugar alternatives, insect repellents, bioplastics, clinical trials, patents, revenue, operating expenses, net loss, initial public offering